Effects of Growth Hormone Administration on Plasma Levels of Proinflammatory Cytokines and Soluble Apoptosis Mediators Fas/FasLigand in Patients with Dilated Cardiomyopathy

Hellenic Journal of Cardiology

Volumn 43, Issue 4, 2002, Pages 20-25

  Adamopoulos, Stamatis ^a   Parissis, John T ^b   Karatzas, Dimitrios ^a   Georgiadis, Michael ^a   Kroupis, Christos ^a   Venetsanou, Koula ^b   Karavolias, George ^a   Karas, Spilios M ^b   Koniavitou, Katerina ^a   Dimitrios TH Kremastinos, ^a   Parissis, Ioannis T ^c  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Apoptosis; Chronic heart failure; Cytokines; Growth hormone; Soluble receptors

Indexed keywords

CYTOKINE; FAS ANTIGEN; FAS LIGAND; GROWTH HORMONE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; EXERCISE TOLERANCE; HORMONAL THERAPY; HUMAN; IMMUNOMODULATION; INFLAMMATION; OXYGEN CONSUMPTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 0842333791     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mann DL, Young JB: Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994; 105: 897-904.
2. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 2101-2106.
3. Nishigaki K, Minatogouchi S, Seishima M, et al: Plasma Fas Ligand, an inducer of apoptosis, and plasma soluble Fas an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 1997; 29: 1214-1220.
4. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 1998; 274: R577-R595.
5. Sasayama S, Matsumori A, Kihara Y: New insights into the pathophysiological role for cytokines in heart failure. Cardiovasc Res 1999; 42: 557-564.
6. Parissis J, Venetsanou K, Ziras N, et al: Clinical correlates and prognostic value of apoptosis mediator soluble forms in patients with congestive heart failure. J Am Coll Cardiol 1998; 32 (Suppl. A): 329 A (Abstract).
7. Okuyama M, Yamaguchi S, Nozaki N, et al: Serum levels of soluble form Fas molecule in patients with congestive heart failure. Am J Cardiol 1997; 79: 1698-1701.
8. Yang R, Bunting S, Gillet N, et al: Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995; 92: 262-267.
9. Houck WV, Pan LC, Kribbs SB, et al: Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure. Circulation 1999; 100: 2003-2009.
10. Volterani M, Manelli F, Cicoira M, et al: Role of growth hormone in chronic heart failure. Therapeutic implications. Drugs 2000; 60: 711-719.
11. Fazio S, Cittadini A, Sabatini D, et al: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-814.
12. Hills M, Armitage P: The two-period cross-over clinical trial. Br J Clin Pharmacol 1979; 8: 7-20.
13. Ferrari R, Angoletti L, Comini L, et al: Oxidative stress during myo-cardial ischemia and heart failure. Eur Heart J 1998; 19 (Suppl. B): B2-B11.
14. Ferrari R, Bachetti T, Confortini R, et al: Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92: 1479-1486.
15. Testa M, Yeh M, Lee P, et al: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28: 964-971.
16. Kawakami H, Shigematsu Y, Ohtsuka T, et al: Increased circulating soluble form of Fas in patients with dilated cardiomyopathy. Jpn Circ J 1998; 62: 873-876.
17. Yamaguchi S, Yamaoka M, Okuyama M, et al: Elevated circulating levels and cardiac secretion of soluble Fas Ligand in patients with congestive heart failure. Am J Cardiol 1999; 83: 1500-1503.
18. Gullestad L, Aukrust P, Veland T, et al: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999; 34: 2061-2067.
19. Mohler ER, Sorensen LC, Ghali JK, et al: Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial. J Am Coll Cardiol 1997; 30: 35-41.
20. Hongo M, Ryoke T, Schoenfeld J, Hunter J, et al: Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy. Basic Res Cardiol 2000; 95: 431-441.
21. Josc VJ, Zechariah TU, George P, et al: Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study. Indian Heart J 1999; 51: 183-185.
22. Beranek JT: Why growth hormone therapy is efficient in heart failure? Eur Heart J 1999; 20: 242-243.
23. Fazio S, Cittadini A, Sabatini D, et al: Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur Heart J 1997; 18: 340-344.
24. Delafontaine P, Brink M: The growth hormone and insulin-like growth factor-1 axis in heart failure. Ann Endocrinol 2000; 61: 22-26.
25. Hussain MA, Schmitz O, Mengel A, et al: Insulin-like growth factor 1 stimulates lipid oxidation, reduces protein oxidation and enhances insulin sensitivity in humans. J Clin Invest 1993; 92: 2249-2256.
26. Zenobi PD, Holzmann P, Glatz Y, et al: Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor 1. Diabetologia 1993; 36: 465-469.
27. Colao A, Marzullo P, Di Somma C, et al: Growth hormone and the heart. Clin Endocrinol 2001; 54(2): 137-154.
28. Ross J, Ryoke T: Effects of growth hormone and insulin-like growth factor 1 in experimental heart failure. Growth Horm IGF Res 1998; 8(Suppl. B): 159-161.